XML 103 R83.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
$ in Thousands
Preferred stock
Common stock
Additional paid-in capital
Accumulated comprehensive (loss) income
Deficit
Total
Balance, beginning of period at Dec. 31, 2018 $ 0 $ 0 $ 555 $ 0 $ (210,596) $ (210,041)
Balance, beginning of period (in shares) at Dec. 31, 2018 3,405 9,583,163        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Effect of exchange transaction         10,956 10,956
Effect of exchange transaction (in shares)   (603,874)        
Issuance of warrants to purchase common stock     1,217     1,217
Settlement of litigation (in shares) (444) (10,540)        
Issuance of common stock upon exercise of stock options and warrants     36     36
Issuance of common stock upon exercise of stock options and warrants (in shares)   423,933        
Stock-based compensation     1,531     1,531
Foreign currency translation adjustment       54   54
Net loss         (59,414) (59,414)
Balance, end of period at Dec. 31, 2019     3,339 54 (259,054) (255,661)
Balance, end of period (in shares) at Dec. 31, 2019 2,961 9,392,682        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation     456     456
Foreign currency translation adjustment       451   451
Net loss         (17,471) (17,471)
Balance, end of period at Mar. 31, 2020     3,816 505 (269,188) (264,867)
Balance, end of period (in shares) at Mar. 31, 2020   8,997,741        
Balance, beginning of period at Dec. 31, 2019     3,339 54 (259,054) (255,661)
Balance, beginning of period (in shares) at Dec. 31, 2019 2,961 9,392,682        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Effect of exchange transaction         7,337 7,337
Effect of exchange transaction (in shares)   (466,711)        
Cancellation of exchange transaction by shareholder (in shares)   1,034,135        
Recognition of beneficial conversion feature related to convertible notes     1,629     1,629
Issuance of warrants to purchase common stock     168     168
Issuance of common stock upon exercise of stock options and warrants     383     $ 383
Issuance of common stock upon exercise of stock options and warrants (in shares)   1,268,265       996,991
Stock-based compensation     4,542     $ 4,542
Foreign currency translation adjustment       (246)   (246)
Net loss         (156,124) (156,124)
Balance, end of period at Dec. 31, 2020     10,061 (192) (407,841) (397,972)
Balance, end of period (in shares) at Dec. 31, 2020 2,961 11,228,371        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Recognition of beneficial conversion feature related to convertible notes     1,126     $ 1,126
Issuance of common stock upon exercise of stock options and warrants (in shares)           6,465,857
Stock-based compensation     784     $ 784
Foreign currency translation adjustment       251   251
Net loss         (82,553) (82,553)
Balance, end of period at Mar. 31, 2021     $ 14,726 $ 59 $ (490,394) $ (475,609)
Balance, end of period (in shares) at Mar. 31, 2021   17,694,228